Nearly 90% with 'obesity disease' in Japan view condition as personal responsibility: poll
TOKYO -- About 90% of patients with "obesity disease" in Japan perceive the medical condition as a personal responsibility, ...
From weight to wellness: New database could transform obesity research
A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
EurekAlert!5d
From weight to wellness: New database transforms obesity research
A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely comprehensive and reliable manner. The initiative, ...
Nasdaq12d
Rhythm Pharmaceuticals Receives Orphan Drug Designation in Japan for Setmelanotide in Acquired Hypothalamic Obesity Treatment
“With this designation now in place in Japan, as well as in Europe, we believe we are well positioned to execute on our global strategy to bring patients with hypothalamic obesity the first-ever ...